INTRODUCTION
For some time steroid chemists have known that small chemical changes in steroid molecules may have profound effects on the biological activity of a compound. For example, a double bond inserted in the cortisone molecule greatly increases its biological activity as a-1, cortisone (meticorten). Likewise, removal of a methyl group from progesterone increases its biological activity, e.g., norprogesterone (Nor-signifying that something has been removed). In 1954 a group of investigators decided to try to increase the progestational activity of ethinyl testosterone (pregneninolone), a known potent oral progestogen, by removing this same methyl group. They succeeded in synthesizing this compound and a closely related one.' These compounds are known as the 19-nortestosterones (testosterone with a methyl group removed from the 19 position).
Early evaluation of these compounds disclosed that the predicted increase in progestational activity was present.'1 Since 1954 a considerable amount of pertinent information has been published concerning these products. It is the purpose of this paper to review the literature on these preparations and to summarize the pharmacological and physiological findings to date. There are four compounds to be considered:
1. 17a methyl-19-nortestosterone (Neosteron-Organon). Progestational Activity In addition to their obvious structural similarities, these compounds have several pharmacological properties in common. The foremost of these properties is their progestational activity. For the most part, these prep-arations were evaluated quantitatively in estrogen-primed rabbits (Clauberg Test). All four were potent progestational compounds on this test
showing from 2y2 to 25 times the activity of progesterone per os."U17, '0
The compounds showed a greater activity than ethinyl testosterone." When the compounds were administered parenterally, there was decreased progestational activity. The compounds showed activity varying from less active to 10 times as active as progesterone.' " When administered directly into the uterus of the rabbit, the compounds showed less than one-fourth the activity of progesterone, probably indicating that some product of metabolism is the active hormone.' " Carbonic anhydrase studies in rabbit endometria, as a measure of progestational activity, showed rather unimpressive results, and mucus changes were atypical." It is not possible to project the results of such animal experiments directly to man.
All four compounds have exhibited some degree of progestational activity in the human, the drugs showing a greater advantage over progesterone when administered by the sublingual and oral routes.7'9'1"'' One compound, 17a methyl-19-nortestosterone (Neosteron), shows 150 times the potency of progesterone and 50 times that of ethinyl testosterone when administered sublingually.7 Parenterally, this great advantage over progesterone is lost, the effects ranging from 10 times the magnitude to less activity than progesterone administered by the same route.9 The drugs produce definite endometrial changes resembling those of progesterone.7' 1' X X" However, Southam and Pincus found that in their patients there was a greater effect on stromal cells than glandular epithelium.=" Basal body temperature is elevated by administration,9" and there appear to be typical progestational cervical mucous changes."'9 Withdrawal bleeding occurs with all four drugs in estrogen-primed women."' The exact status of withdrawal bleeding caused by these compounds is rather confused since three of the compounds are known to be contaminated with estrogen. "" X 2 Alkaline phosphatase studies show changes more consistent with proliferative stages than with true secretory endometrium.' These studies would indicate that there is a distinct possibility of some variation from true progestational activity.
Prolonged administration of two of these compounds has demonstrated excellent decidual response in both human and monkey endometria. 19 " it is possible that as different esters of these compounds are investigated, similar changes will be demonstrated.
Anabolic Activity
The above-mentioned compounds, despite their rather poor androgenic activity, exhibit profound anabolic and myotrophic effects in animals. 8' B' r In studies on the levator ani muscle of rats, activity similar to testosterone propionate is noted." In the human, this anabolic and myotrophic effect is less easily demonstrated. Ferrin7 showed no anabolic effect in humans with the methyl product (Neosteron), and Sachs' and Spencer8' showed varying amounts of anabolic activity with the ethyl product (Nilevar).
New compounds with progestational activity BUCKNER, HERRMANN Reproduction There has been much interest in the effect these compounds have on the physiology of reproduction. They have multiple actions in preventing conception. All four compounds inhibit ovulation both in animals and humans."' If ovulation does occur, there is some evidence that corpus luteum function is too poor to support a subsequent pregnancy.' This action may be due to either a direct effect on the ovary, or to secondary ovarian response to decreased gonadotrophin production. However, in most cases the ovulation response seems to precede and outweigh any measurable depression of the gonadotrophin titers. There is also some evidence that at least one of the compounds may have a damaging effect on any ovum that may be fertilized.' 7 Heller,'0 in a controlled series of human experiments, has demonstrated that these compounds, as well as progesterone, cause complete azoospermia, although there may be some residual spermatogenesis in biopsy specimens. The compounds support pregnancy poorly. Pincus' claims that the ethyl compound (Nilevar) is a "potent maintainer of implantation." However, Saunders and Drill2"7 have shown that this compound is only 25 per cent as effective as progesterone in maintaining pregnancy. 17a ethinyl-5(10)-estraen-17,8-01-3-one (Enovid) even seems to antagonize exogenous progesterone in its ability to maintain pregnancy.'
The decidual response shown by these drugs has been utilized by Rock et aL to produce a so-called pseudo-pregnancy and "rebound."""' The drugs were administered through two or more succeeding cycles with resultant amenorrhea and symptoms of early pregnancy. Rock noted that after cessation of therapy, a significant number of pregnancies occurred. Southam,T however, in a similar experiment demonstrated that the same degree of "rebound" could be obtained with progesterone and, in fact, the number of pregnancies after the "rebound" probably was not significantly higher than the number to be expected in an untreated series followed for a similar length of time. Estrogenic Activity All the compounds have some degree of inherent estrogenic activity besides the estrogen contamination mentioned earlier. The effect in the methyl (Neosteron) and ethyl (Nilevar) compounds is probably negligible,"' ' the ethyl product (Nilevar) showing some anti-estrogenic activity."5 The ethinyl product (Norlutin) exhibits some definite estrogenic effects in rat experiments, and in humans probably causes some minimal estrogenic effect."'27 Jadrijevic et al." have demonstrated some antiestrogenic activity in the guinea pig. The estrogenic effects of 17a ethinyl-5(10)-estraen-17,/-01-3-one are high enough to be of significance in humans, and quantitation in animals shows it to have 1 to 7 per cent the activity of estrone sulfate." Since this estrogenic activity is even higher in the commercially available contaminated product (Enovid), the manufacturers have added estrogen to try to eliminate any break-through bleeding.
Effects on Gonadotrophin
In animals the compounds exhibit gonadotrophin-inhibiting activity.8"1 This inhibition is less definitely established in humans. The antigonadotrophic effect is not related to the androgenicity of the compounds.8
Metabolism
The intermediary metabolism of the four compounds is unknown. The knowledge of their effect on intermediary metabolism is equally sketchy. They show no effect on survival of adrenalectomized rats.' The ethyl compound (Nilevar) increases the serum a2 and /8 globulins and the /8 lipoproteins.' They produce relatively poor sodium retention.1' The urinary pregnanediol levels are unaffected, as are the 17-ketosteroids and 17-OHsteroids, according to Greenblatt. However, Pincus' claims a decrease of these same steroids. He also reports a decrease in blood progesterone levels and changes in the protein-binding of 17-OH-steroids. 19 terone (Nilevar) would seem to be the best anabolic agent of the four, with rather poor ability to prevent break-through bleeding and minimal androgenic activity. 17a ethinyl-19-nortestosterone (Norlutin) and 17a ethinyl-5(10)-estraen-17,8-01-3-one (Enovid) demonstrate good progestational activity with minimal anabolic activity. However, both have definite estrogen effects. This has been compensated to some extent in Enovid by the addition of estrogen, so administration of the compound is essentially combined estrogen-progesterone therapy (Table 1 ).
